It is produced by the strain of Semisynthetic third generation oral cephalosporin. The activity of Ceftibuten against enterobacteriaceae which can produce broad-spectrum β-lactamase was superior to cefotaxime and amtriannan, the activity of Ceftibuten against gram-negative bacteria was stronger than cefacolol, but the activity against gram-positive bacteria was poor, and the activity against Streptococcus pneumoniae was only 1/8 of Ceftibuten. It is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.